Circulating DNA-markers in lung cancer: changes in retrotrasposons methylation status in response therapy and during the post-treatment follow-up A. A. Ponomaryova, A. Y. Dobrodeev, A. A. Bondar [et.al.]
Material type:
ArticleSubject(s): онкомаркеры | рак легкого | циркулирующая опухолевая ДНК | метилированиеGenre/Form: статьи в сборниках Online resources: Click here to access online
In:
The 22nd International Charles Heidelberger symposium on cancer research : proceedings of the International symposium, 17-19 September 2018 P. 88-89Abstract: Malignant cell transformation is accompanied by two processes of DNA methylation changes:
hypermethylation in CpG islands of tumor suppressor genes and global hypomethylation in repetitive
DNA sequences (retrotransposons) [1, 2]. The composition of circulating DNA (cirDNA) from
plasma and cell-surface-bound cirDNA (csb-cirDNA) was shown earlier to be altered in the blood
of cancer patients due to accumulation of tumor-specific aberrantly methylated DNA fragments,
which are currently considered valuable cancer markers [3, 4].
Библиогр.: 4 назв.
Malignant cell transformation is accompanied by two processes of DNA methylation changes:
hypermethylation in CpG islands of tumor suppressor genes and global hypomethylation in repetitive
DNA sequences (retrotransposons) [1, 2]. The composition of circulating DNA (cirDNA) from
plasma and cell-surface-bound cirDNA (csb-cirDNA) was shown earlier to be altered in the blood
of cancer patients due to accumulation of tumor-specific aberrantly methylated DNA fragments,
which are currently considered valuable cancer markers [3, 4].
There are no comments on this title.